Q1 2025 Certara Inc Earnings Call Transcript
Key Points
- Certara Inc (CERT) reported a 10% year-over-year revenue growth for Q1 2025, reaching $106 million.
- The company achieved a 12% increase in bookings, with software bookings growing by 23% and services bookings by 7%.
- Certara's Non-Animal Navigator solution has generated significant interest following the FDA's announcement to phase out animal testing.
- The company launched the 24 version of its Simcyp simulator, featuring numerous new enhancements and features.
- Certara announced a $100 million share repurchase authorization, reflecting confidence in its strategic growth initiatives.
- Certara faces continued headwinds from IRA price controls and an erratic capital-raising environment for biotech.
- There is softness in demand from Tier 1 customers for biosimulation services.
- The software net retention ratio was lower than historical averages, at 102% for the quarter.
- The company anticipates a challenging end market environment, with biotech funding and Tier 1 pharma decision-making slowness.
- Certara's primary use of capital remains focused on M&A and organic strategic investments, which may limit flexibility in other areas.
Good day, and thank you for standing by. Welcome to the Certara first quarter 2025 earnings conference call. (Operator Instructions) Please be advised that today's conference is being recorded. I would now like to hand the conference over to your speaker today, David Deuchler, Investor Relations. Please go ahead.
Good afternoon, everyone. Thank you all for participating in today's conference call. On the call from Certara, we have William Feehery, Chief Executive Officer; and John Gallagher, Chief Financial Officer. Earlier today, Certara released financial results for the quarter ended March 31, 2025. A copy of the press release is available on the company's website.
Before we begin, I would like to remind you that management will make statements during this call that include forward-looking statements and actual results may differ materially from those expressed or implied in the forward-looking statements.
Please refer to slide 2 in the accompanying materials for additional information,
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
